Stock Alert: Atreca Down 18%

Shares of Atreca, Inc. (BCEL) are currently losing nearly 18% on Thursday morning despite no stock-specific news.

BCEL is currently trading at $15.11, down $3.31 or 17.96%, on the Nasdaq.

Atreca is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types.

The company on Wednesday announced the pricing of its previously announced underwritten public offering of 7 million Class A common stock and 781 thousand Class B common stock, each at a price to the public of $16.00 per share.

Gross proceeds to Atreca from the offering are expected to be $125.0 million.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
McDonald's says equal pay for women is just the beginning, while conforming that the fast-food giant pays women globally 99.85 cents on the dollar for similar work, taking into account legitimate pay drivers such as level, location, experience, and performance. The company added that it is on track to close that identified gap in 2022. Verizon Communications Inc. (VZ) said, on an adjusted basis, its third-quarter earnings per share rose 12.8 percent from a year ago. The company said its earnings were highlighted by revenue and customer growth as more than one in four Consumer wireless phone customers now have a 5G-capable device. The... While reporting financial results for the third quarter on Wednesday, Abbott Laboratories (ABT) raised its earnings and adjusted earnings guidance for the full-year 2021. For fiscal 2021, the company continues to project earnings from continuing operations in a range of $3.55 to $3.6 per share and...
Follow RTT